Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH

Christopher R. King, Stephen J. Freedland, Martha Kennedy Terris, William J. Aronson, Christopher J. Kane, Christopher L. Amling, Joseph C. Presti

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objectives: Preoperative prostate-specific antigen (PSA) velocity (PSAV), the rate of PSA rise preceding diagnosis, predicts for relapse and cancer death after prostatectomy or radiotherapy. We studied the timing, cutoff levels, and method of calculation to better define its usefulness. Methods: The rates of biochemical relapse were examined in 471 patients who underwent radical prostatectomy (RP) with previous PSA history available. PSAV was calculated by two methods, as the difference between two PSAs divided by time, or as the slope of all available PSAs within that interval. Kaplan-Meier relapse-free survival was compared among the groups with various intervals and cutoff levels in their preoperative PSAV definition. Univariate and multivariate analysis examined all preoperative factors and PSAV for their association with relapse. Results: The two methods of PSAV calculation yielded values within 5% of each other (R2 = 0.91). A PSA history that precedes RP by at least 12 months is necessary. A PSAV cutoff level of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr appeared optimal for a PSA interval spanning 12 to 24 months before RP (P = 0.008). PSAV using a longer interval (24 to 36 months) before RP appeared more sensitive, with a cutoff of 1 ng/mL/yr or less versus greater than 1 ng/mL/yr (P = 0.029) and 2 ng/mL/yr or less versus greater than 2 ng/mL/yr (P = 0.0041) associated with relapse. A preoperative PSAV of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr was an independent factor associated with the risk of relapse after RP. Conclusions: The results of our study have shown that preoperative PSAV is independently associated with relapse after RP. However, a minimum interval of 12 months before RP is needed, and a PSAV cutoff level of 2 ng/mL/yr appears optimal. A simple two-point method of calculating PSAV is reliable.

Original languageEnglish (US)
Pages (from-to)732-737
Number of pages6
JournalUrology
Volume69
Issue number4
DOIs
StatePublished - Apr 1 2007

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
History
Radiotherapy
Multivariate Analysis
Survival
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy : A Report from SEARCH. / King, Christopher R.; Freedland, Stephen J.; Terris, Martha Kennedy; Aronson, William J.; Kane, Christopher J.; Amling, Christopher L.; Presti, Joseph C.

In: Urology, Vol. 69, No. 4, 01.04.2007, p. 732-737.

Research output: Contribution to journalArticle

King, Christopher R. ; Freedland, Stephen J. ; Terris, Martha Kennedy ; Aronson, William J. ; Kane, Christopher J. ; Amling, Christopher L. ; Presti, Joseph C. / Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy : A Report from SEARCH. In: Urology. 2007 ; Vol. 69, No. 4. pp. 732-737.
@article{5dcca938dfe54de29fe7321b8d9b4244,
title = "Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH",
abstract = "Objectives: Preoperative prostate-specific antigen (PSA) velocity (PSAV), the rate of PSA rise preceding diagnosis, predicts for relapse and cancer death after prostatectomy or radiotherapy. We studied the timing, cutoff levels, and method of calculation to better define its usefulness. Methods: The rates of biochemical relapse were examined in 471 patients who underwent radical prostatectomy (RP) with previous PSA history available. PSAV was calculated by two methods, as the difference between two PSAs divided by time, or as the slope of all available PSAs within that interval. Kaplan-Meier relapse-free survival was compared among the groups with various intervals and cutoff levels in their preoperative PSAV definition. Univariate and multivariate analysis examined all preoperative factors and PSAV for their association with relapse. Results: The two methods of PSAV calculation yielded values within 5{\%} of each other (R2 = 0.91). A PSA history that precedes RP by at least 12 months is necessary. A PSAV cutoff level of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr appeared optimal for a PSA interval spanning 12 to 24 months before RP (P = 0.008). PSAV using a longer interval (24 to 36 months) before RP appeared more sensitive, with a cutoff of 1 ng/mL/yr or less versus greater than 1 ng/mL/yr (P = 0.029) and 2 ng/mL/yr or less versus greater than 2 ng/mL/yr (P = 0.0041) associated with relapse. A preoperative PSAV of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr was an independent factor associated with the risk of relapse after RP. Conclusions: The results of our study have shown that preoperative PSAV is independently associated with relapse after RP. However, a minimum interval of 12 months before RP is needed, and a PSAV cutoff level of 2 ng/mL/yr appears optimal. A simple two-point method of calculating PSAV is reliable.",
author = "King, {Christopher R.} and Freedland, {Stephen J.} and Terris, {Martha Kennedy} and Aronson, {William J.} and Kane, {Christopher J.} and Amling, {Christopher L.} and Presti, {Joseph C.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.urology.2007.01.019",
language = "English (US)",
volume = "69",
pages = "732--737",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy

T2 - A Report from SEARCH

AU - King, Christopher R.

AU - Freedland, Stephen J.

AU - Terris, Martha Kennedy

AU - Aronson, William J.

AU - Kane, Christopher J.

AU - Amling, Christopher L.

AU - Presti, Joseph C.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Objectives: Preoperative prostate-specific antigen (PSA) velocity (PSAV), the rate of PSA rise preceding diagnosis, predicts for relapse and cancer death after prostatectomy or radiotherapy. We studied the timing, cutoff levels, and method of calculation to better define its usefulness. Methods: The rates of biochemical relapse were examined in 471 patients who underwent radical prostatectomy (RP) with previous PSA history available. PSAV was calculated by two methods, as the difference between two PSAs divided by time, or as the slope of all available PSAs within that interval. Kaplan-Meier relapse-free survival was compared among the groups with various intervals and cutoff levels in their preoperative PSAV definition. Univariate and multivariate analysis examined all preoperative factors and PSAV for their association with relapse. Results: The two methods of PSAV calculation yielded values within 5% of each other (R2 = 0.91). A PSA history that precedes RP by at least 12 months is necessary. A PSAV cutoff level of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr appeared optimal for a PSA interval spanning 12 to 24 months before RP (P = 0.008). PSAV using a longer interval (24 to 36 months) before RP appeared more sensitive, with a cutoff of 1 ng/mL/yr or less versus greater than 1 ng/mL/yr (P = 0.029) and 2 ng/mL/yr or less versus greater than 2 ng/mL/yr (P = 0.0041) associated with relapse. A preoperative PSAV of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr was an independent factor associated with the risk of relapse after RP. Conclusions: The results of our study have shown that preoperative PSAV is independently associated with relapse after RP. However, a minimum interval of 12 months before RP is needed, and a PSAV cutoff level of 2 ng/mL/yr appears optimal. A simple two-point method of calculating PSAV is reliable.

AB - Objectives: Preoperative prostate-specific antigen (PSA) velocity (PSAV), the rate of PSA rise preceding diagnosis, predicts for relapse and cancer death after prostatectomy or radiotherapy. We studied the timing, cutoff levels, and method of calculation to better define its usefulness. Methods: The rates of biochemical relapse were examined in 471 patients who underwent radical prostatectomy (RP) with previous PSA history available. PSAV was calculated by two methods, as the difference between two PSAs divided by time, or as the slope of all available PSAs within that interval. Kaplan-Meier relapse-free survival was compared among the groups with various intervals and cutoff levels in their preoperative PSAV definition. Univariate and multivariate analysis examined all preoperative factors and PSAV for their association with relapse. Results: The two methods of PSAV calculation yielded values within 5% of each other (R2 = 0.91). A PSA history that precedes RP by at least 12 months is necessary. A PSAV cutoff level of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr appeared optimal for a PSA interval spanning 12 to 24 months before RP (P = 0.008). PSAV using a longer interval (24 to 36 months) before RP appeared more sensitive, with a cutoff of 1 ng/mL/yr or less versus greater than 1 ng/mL/yr (P = 0.029) and 2 ng/mL/yr or less versus greater than 2 ng/mL/yr (P = 0.0041) associated with relapse. A preoperative PSAV of 2 ng/mL/yr or less versus greater than 2 ng/mL/yr was an independent factor associated with the risk of relapse after RP. Conclusions: The results of our study have shown that preoperative PSAV is independently associated with relapse after RP. However, a minimum interval of 12 months before RP is needed, and a PSAV cutoff level of 2 ng/mL/yr appears optimal. A simple two-point method of calculating PSAV is reliable.

UR - http://www.scopus.com/inward/record.url?scp=34147137270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147137270&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.01.019

DO - 10.1016/j.urology.2007.01.019

M3 - Article

C2 - 17445660

AN - SCOPUS:34147137270

VL - 69

SP - 732

EP - 737

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -